Kornimate/medical-research-clean huggingface dataset:
magnesium-l-threonate for sleep quality post-arthroplasty

Conditions: Sleep; Knee Osteoarthritis

Summary: the study team is conducting a study to see if magnesium-l-threonate (mgt) can help improve how well participants sleep and reduce pain after total joint replacement surgery


Eligibility criteria:
inclusion criteria: * patients undergoing primary total knee or hip arthroplasty at the university of miami hospital * patients \> 18 years of age * subjects must be capable of providing informed consent * english or spanish-speaking exclusion criteria: * previous total joint arthroplasty at the surgical site * history of sleeping disorders, including narcolepsy, sleep apnea, insomnia, parasomnias, and restless leg syndrome. * history of complex regional pain syndrome in ipsilateral extremity * history of demyelinating disorder or neurologic deficit in the affected extremity * history of psychiatric disorders that could impact sleep, such as untreated depression, bipolar disorder, or schizophrenia. * participants taking medications known to cause significant sedation or insomnia. * pregnant or breastfeeding * being treated for a diagnosis other than primary osteoarthritis (e.g. pelvic/femur fracture) * patients with known substance use disorder within 6 months of surgery * liver failure, via clinical diagnosis or international normalized ratio greater than 1.5 or prothrombin time greater than 40 * chronic kidney disease or glomerular filtration rate less than 30 ml/min
a study of an automated insulin delivery system in adult participants with type 1 diabetes mellitus (t1d)

Conditions: Type 1 Diabetes Mellitus

Summary: the automated insulin delivery (aid) system is an investigational insulin delivery device being developed for use for participants with diabetes. the purpose of this study is to assess the safety of the aid system and to test whether the aid system functions as designed. the study will last about 3 months with up to 6 days of inpatient time.


Eligibility criteria:
* participants with t1dm for at least 2 years and who have used an insulin delivery system with any rapid-acting insulin analog for the preceding 6 months * have a body mass index of 18.5 to 37 kilogram per meter squared * have a hemoglobin a1c level ≥6.0% and ≤9.0% exclusion criteria: * have known allergies or history of hypersensitivity to insulin lispro * have had an episode of severe hypoglycemia within the past 6 months * have had more than 1 episode of diabetic ketoacidosis in the past 6 months
hepatic pseudoaneurysms after trauma

Conditions: Pseudoaneurysm; Abdominal Trauma

Summary: hepatic pseudoaneurysm (hpa) is a rare complication after liver trauma, yet it is potentially fatal, as it can lead to sudden severe haemorrhage. the risk of developing posttraumatic hepatic pseudoaneurysm is one of the reasons why some trauma centres do follow-up ct of patients with liver injuries to take the therapeutic consequence. the aim of this study was to investigate the occurrence of hpa post liver trauma.


Eligibility criteria:
inclusion criteria: * conservatively managed liver trauma patients with follow-up ct or us exclusion criteria: * patients who underwent laparotomy because of other intra-abdominal injuries
study of gc1008 in patients with idiopathic pulmonary fibrosis (ipf)

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this study is designed to investigate whether gc1008, an antibody that neutralizes tgfb, is safe in treating patients with idiopathic pulmonary fibrosis. the highest dose without excessive side effects will be identified. tests will determine how long gc1008 is in the body and how it is excreted.


Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent prior to any study-related procedures. * patients should have an established diagnosis of ipf. * pulmonary function tests (pfts): fvc ≥ 50% and dlco ≥ 25% of normal predicted values. * able to walk at least 500 feet (150 meters) during the 6-minute walk test (6mwt). during the 6mwt the patient must not require greater than 51/min supplemental oxygen to maintain oxygen saturation \> 80% exclusion criteria: * women who are pregnant or lactating; or who plan to become pregnant within 9 months after the infusion. * women of childbearing potential or men who are considering fathering a child unless taking medically acceptable contraceptive precautions; * history of clinically significant environmental exposure, including dust, molds, asbestos, pigeons or other birds that may result in interstitial lung disease, or ingestion of a drug known to cause pulmonary fibrosis such as bleomycin. * history of clinically significant respiratory diseases other than ipf. * history of clinically significant cardiac, hepatic, or renal disease. * history of cancer, precancerous state (e.g. familial polyposis, brca1, brca2), other than non-melanomatous skin cancer, within 5 years prior to screening. * use of any investigational drug administered as part of a clinical trial within 12 weeks before screening. * other pathology that might interfere with the assessment of the safety or efficacy of the test article. * other clinically significant, uncontrolled medical condition that, in the investigator's opinion, might interfere with the assessment or follow-up.

Keywords: ipf idiopathic pulmonary fibrosis
analysis of chemical pattern exhaled by different neoplasms through chemoresistive nanostructured sensors

Conditions: Tumor, Solid

Summary: the aim of the study is to identify a pattern of chemoresistive sensors able to recognise the presence of a tumoral pathology from a health state through the analysis of volatile organic compounds inside the specimen. the chemoresistive nanostructured sensors are into an innovative patented device scent b1 which can analyse different specimens: blood samples, tissue biopsies, cell cultures. in this study scent b1 wil be used to compare the measures of: * tumoral and health tissues taken from different neoplasms after their surgical resection * blood samples from healthy and tumor affected people * pre and post- operative blood samples of tumor affected people

scent b1 is a patented device constituted by four chemoresistive nanostructured sensors able to vary their conductance depending on chemical substances present in the environment. these sensors are extremely sensitive as they can identify substances at a concentration of tens parts per billion such as volatile organic compounds derived from tumor cells metabolism. every sensor answers differently from the others and the aim of the study is to find the best array of sensors able to discriminate among tumoral and healthy specimens. different specimens are tested: tissue biopsies and blood samples. blood samples are collected from patients undergoing surgical resection of the neoplasm. a first blood sample is collected before the surgery and it is compared to a control sample taken from an healthy volunteer. the second blood sample is taken from the patient during a follow-up visit after the finish of any post-operative therapy. blood samples are conserved at ambient temperature and analyzed by scent b1 on the same day of the collection. health and tumoral tissue biopsies are collected from surgical resection specimens, kept in breeding ground, cleaned from bacteria, adipose tissue and other contaminants and finally processed in scent b1 on the day after the collection. the four sensors' outputs are combined in statistical analysis in order to define the threshold between health and tumor affected specimens.

Eligibility criteria:
inclusion criteria: * patients who undergo to open or laparoscopic surgery for colorectal cancer in election regimen * patients who underwent to open or laparoscopic surgery for colorectal cancer and who have finished chemotherapy or radiotherapy yet exclusion criteria: * patients operated in emergency regimen * pregnant women

Keywords: volatile organic compounds colorectal cancer non invasive diagnostic tests medical device
multimodal computed tomography in patients with acute hemorrhagic stroke

Conditions: Acute Hemorrhagic Stroke

Summary: acute hemorrhagic stroke is a series of neurosurgical diseases characterized by bleeding with high morbidity and mortality. it accounts for about 20% of all strokes worldwide and mainly includes subtypes such as intracerebral hemorrhage (ich) and subarachnoid hemorrhage (sah). multimodal computed tomography including non-contrast computed tomography, computed tomography angiography and computed tomography perfusion, is of great important in understanding pathophysiological changes, evaluating prognosis and guiding interventions in these diseases.

study overview: the data of the population in the mactahs study will be prospectively collected. the ct strategies for acute hemorrhagic stroke are mainly three categories: non-contrast computed tomography, computed tomography angiography and computed tomography perfusion. each participants will be followed at least until 1 year after discharge. finally, investigators will clarify the prognostic value of multimodal ct for patients with acute hemorrhagic stroke. sample size: about 10000 patients will be enrolled in this study. all the population will be expected to undergo non-contrast computed tomography, computed tomography angiography and computed tomography perfusion. study endpoints: neurological functional outcomes, delayed ischemia and infarction, recurrent bleeding, cognition and emotional dysfunction, systemic in-hospital systemic complications, rehabilitation and recovery status will be evaluated and follow-up would be completed.

Eligibility criteria:
inclusion criteria: 1. age ≥ 18, ≤ 85 years; 2. presence with hemorrhagic stroke exclusion criteria: 1. with a history of previous history of ischemic/hemorrhagic stroke; 2. admission to the emergency department more than a week after symptom onset; 3. serious medical history or existing comorbidities; 4. physical disability due to previous diseases; 5. prior treatment such as external ventricular drainage, digital subtraction angiography and lumbar puncture in other institution; 6. poor original image quality; 7. incomplete follow-up.

Keywords: acute hemorrhagic stroke multimodal ct prognosis
a study to learn about the patients with covid-19 prescribed paxlovid in morocco

Conditions: COVID-19 Drug Treatment

Summary: the purpose of this study is to collect information on the: * general information of a group of people such as their age, sex, and other facts. * clinical information of the patients such as any other illness before having covid 19. in adult patients with covid-19 who have been prescribed nirmatrelvir and ritonavir treatment. this study will be conducted in morocco. the study will capture information of the adult covid-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. the inpatients will be admitted in the hospital for other reasons than covid-19. this study will have about 150 patients. the study will involve collection of patient information from medical records. the information collected can be either from papers or from computers. the study will include patient information of those who: * are confirmed to have covid-19 infection during the study period from 01 june 2022 to 30 june 2023. * are 18 years of age or older. * are prescribed nirmatrelvir and ritonavir. this study will help to inform decision-making on use of paxlovid at the national level.


Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection during the study period from 01 june 2022 to 30 june 2023 * nirmatrelvir, ritonavir written prescription exclusion criteria: * there are no exclusion criteria for this study.

Keywords: treatment covid patient paxlovid morocco
neurostimulation and cognitive intervention in alzheimer's disease

Conditions: Alzheimer's Disease

Summary: this study is a double blind, sham-controlled clinical trial aiming to compare the long-term effects of stimulation in alzheimer's disease (ad). sixty early ad patients will take part in a phase ii/iii clinical study over a 1-year period. the study involves transcranial direct current stimulation (tdcs), cognitive training (ct), detailed neuropsychological and neurological testing. these assessments will occur at baseline, then again at two month (end point). those who achieve clinical improvement with neurostimulation and cognitive therapy will be invited to receive treatment for 12 months as part of a follow-up study.

the patients will be randomized into 1 of 4 groups: active tdcs plus real ct, active tdcs plus placebo ct, sham tdcs plus real ct, sham tdcs plus placebo ct. each group will receive treatment for 30 minutes a day, 3 days a week for 8 weeks.

Eligibility criteria:
inclusion criteria: * male or female age 60-90 years * patients diagnosed with alzheimer's disease, according to the dsm-iv (diagnostic and statistical manual of mental disorders) and nincds-adrda (national institute for communicative disorders and stroke - alzheimer's disease and related disorders association) criteria * score between 18 and 26 on the mini mental state examination * have a cdr (clinical dementia rating) of 1.0 * if medicated for ad, then use of cholinesterase inhibitors, for at least 3 months and on stable dose for at least 60 days prior to screening. exclusion criteria: * pre-existing structural brain abnormalities, * other neurologic or psychiatric diagnoses * transcranial direct current stimulation criteria: patients with implanted metallic or electronic devices; pacemaker; seizures; pregnancy; any other condition that might limit or interfere in the sensorimotor system
study to assess the change in disease state when subcutaneous risankizumab injection is given to adult participants with psoriasis in taiwan

Conditions: Psoriasis

Summary: psoriasis (pso) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health outcomes including quality of life (qol). the main objective of this study is to characterize the durability of response of risankizumab compared to other biologics measured by the psoriasis area and severity index (pasi) 90 response in adult participants with moderate to severe chronic plaque psoriasis who are either new or have used a biological treatment in the past. risankizumab is a drug approved for the treatment of moderate-to-severe plaque psoriasis. participants who are prescribed risankizumab or other comparator drugs in the real world setting are enrolled in this study. data from a total of approximately 240 participants; 160 using risankizumab and 80 using other biologics will be evaluated across taiwan. participants will receive subcutaneous risankizumab injection or or other biologic as prescribed by their physician. data from these participants will be collected for approximately 2 years. there may be a higher burden for participants in this study compared to standard of care. participants will attend regular visits per routine clinical practice. the effect of the treatment will be checked by medical assessments, checking for side effects, and by questionnaire.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of moderate to severe chronic plaque-type psoriasis diagnosed by a specialist t at the time of recruitment. * initiating an approved biologic treatment for psoriasis as per regulatory and reimbursement policy in taiwan. physician's decision with any of the above-mentioned treatments must have been reached prior to and independently of recruitment in the study. * treatments prescribed in accordance to both the product monograph, regulatory and reimbursement policies in taiwan. exclusion criteria: - participation in an interventional clinical trial, concurrently or within the last 30 days. participation in another pmos or registry is acceptable.

Keywords: psoriasis risankizumab skyrizi plaque psoriasis
kt vs iastm on upper trapezius myofascial trigger points to compare effect of kt vs iastm on pain intensity, pain pressure threshold, cervical range of motion and functional disability level.

Conditions: Myofacial Pain Syndromes

Summary: this study would answer the following question: is there a difference in the effects between iastm and kt on pain intensity level, pain pressure threshold, cervical range of motion (rom), functional disability level and satisfaction level in subjects with upper trapezius myofascial trigger points? the aims of this study are: 1. to investigate the effect of kt and iastm on pain intensity level in subjects with upper trapezius myofascial trigger points. 2. to investigate the effects of kt and iastm on pain pressure threshold in subjects with upper trapezius myofascial trigger points. 3. to investigate the effects of kt and iastm on cervical range of motion (rom) in subjects with myofascial trigger points. 4. to investigate the effect of kt and iastm on functional disability level in subjects with upper trapezius myofascial trigger points. 5. to investigate the effects of kt and iastm on satisfaction level in subjects with myofascial trigger points.


Eligibility criteria:
inclusion criteria: - 1) fifty subjects with age ranged from 18 to 23 years old (formen et al., 2014). 2) from both genders with normal bmi ranges between 18.5:24.9 kg/m2. had mtrps of unilateral ut muscle (shamseldeen et al., 2023). exclusion criteria: * 1. history of whiplash injury (emshi et al., 2021). 2. history of head, neck, cervical spine or shoulder surgery (emshi., et al 2021) 3. history of cervical radiculopathy (emshi et al., 2021) 4. patients with malignancy (shamseldeen et al., 2023). 5. cervical spine fractures (shamseldeen et al., 2023). 6. myelopathy (shamseldeen et al., 2023). 7. having undergone physical therapy within the past three months before the study. 8. non - rheumatologic diseases as multiple sclerosis, thyroid dysfunction and chronic infection. 9. rheumatologic condition as poly-articular osteoarthritis, rheumatoid arthritis and advanced cervical spine degenerative diseases. 10. presence of skin diseases (luz júnior et al., 2015). 11. pregnancy (luz júnior et al., 2015).
treatment with beta-blockers after myocardial infarction without reduced ejection fraction"

Conditions: Myocardial Infarction

Summary: reboot clinical trial will study whether long-term maintenance beta-blockers therapy results in a clinical benefit after heart attack without reduced left ventricular function. half of the participants will be randomized to receive long-term beta-blocker therapy and the other half to no beta-blocker therapy after hospital discharge. all patients will be followed up for up to 5 years to determine the occurrence of adverse events (all cause mortality, re-infarction, and heart failure admission).

pragmatic, controlled, prospective, randomized, open-label, blinded endpoint clinical trial testing the benefits of beta-blocker maintenance therapy in patients discharged after an acute myocardial infarction (mi). patients being discharged after an acute mi, with or without st-segment elevation, and with a left ventricular ejection fraction \>40%, and without history of heart failure (hf) prior to study inclusion, will be recruited. at discharge, patients will be randomized (1:1) to receive beta-blocker therapy (agent and dose according to treating physician) or no beta-blocker therapy. primary outcome is the 5 years incidence of mace (all cause mortality, reinfarction, heart failure admission).

Eligibility criteria:
inclusion criteria: * ≥18 years old * admitted for stemi or nstemi and invasive management (i.e. coronary angiography during index hospitalization). * lvef\>40% as evaluated by any imaging technique anytime during hospitalization. * signed informed consent exclusion criteria: * known allergy or intolerance to beta-blockers * absolute contraindication to beta-blocker therapy according to treating physician judge * prior history of hf, killip class on admission or during hospitalization ≥ ii * severe valvular heart disease (\> 3+ for aortic or mitral insufficiency, aortic or mitral valve area ≤1.0 cm2). * any condition (appart from ami) that requires beta-blocker prescription on discharge according to treating physician judge * any medical condition that, in the investigator´s judgment, would seriously limit life expectancy (less than one year), * patients participating in other clinical trials
adherence to aromatase inhibitors: the role of partners

Conditions: Breast Cancer Survivors

Summary: this is a qualitative study which explores the role that partners play in breast cancer survivors adherence to aromatase inhibitors and management of their side effects. both patients and their partners will be interviewed (separately) in order to capture multiple perspectives. the target number of subjects is 64 (32 patients and 32 partners). the primary method of data collection will be face-to-face semi-structured interviews. these interviews will be audio-recorded.


Eligibility criteria:
inclusion criteria: * women and partners of women with stage i-iii breast cancer who 1. have completed primary cancer treatments (surgery, chemotherapy, radiotherapy) 2. have experienced ai side effects 3. live with a romantic partner. exclusion criteria:
reduction of smoking in cardiac disease patients

Conditions: Cardiovascular Disease; Tobacco Use Disorder

Summary: this study evaluates the effect of smoking reduction vs usual care (quitting advice only) for individuals with peripheral arterial disease who smoke.

this study randomly assigns smokers who do not have a quit date set to either a smoking reduction grop or usual care group. the smoking reduction group receives behavioral counseling on smoking reduction and nicotine patch and/or gum to reduce the number of cigarettes smoked per day by at least 50%. the usual care group is given brief advice to quit smoking and referral to local cessation services. to be included in the study, participants must have peripheral arterial disease (defined as ankle brachial index equal to or less than 0.85 or history of prior revascularization) and they must be daily smokers (defined as at least 1 cigarette, cigar, or tobacco pipe daily). participants complete questionnaires that measure mood, functional ability, smoking history, and motivation to quit smoking. participants will be followed in this study for up to 24 months.

Eligibility criteria:
inclusion criteria: * to be included in the study, participants must have peripheral arterial disease (defined as ankle brachial index equal to or less than 0.85 or history of prior revascularization) and they must be daily smokers (defined as at least 1 cigarette, cigar, or tobacco pipe daily).

Keywords: smoking cessation cardiovascular disease smoking reduction nicotine replacement